BlackRock, Inc. 13D and 13G filings for TScan Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-16 7:02 pm Sale | 2025-06-30 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 958,373 1.800% | -1,867,450 (-66.09%) | Filing |
| 2025-04-24 09:12 am Sale | 2025-03-31 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 2,825,823 5.400% | -1,807,453 (-39.01%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 4,633,276 9.500% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 4,633,276 9.500% | 3,366,088 (+265.63%) | Filing |
| 2023-06-08 1:25 pm Sale | 2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 1,267,188 3.000% | -246,758 (-16.30%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 1,513,946 8.000% | 15,408 (+1.03%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX | BlackRock Inc. BLK | 1,498,538 8.000% | 1,498,538 (New Position) | Filing |